Does the media refer more to ALEC or CGEM?

In the previous week, Alector had 4 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 6 mentions for Alector and 2 mentions for Cullinan Therapeutics. Cullinan Therapeutics' average media sentiment score of 1.02 beat Alector's score of 0.93 indicating that Cullinan Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alector 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cullinan Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SPRY or ALEC?

In the previous week, Alector had 4 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 6 mentions for Alector and 2 mentions for ARS Pharmaceuticals. ARS Pharmaceuticals' average media sentiment score of 0.93 equaled Alector'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ARS Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alector 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, MGTX or ALEC?

MeiraGTx has higher revenue and earnings than Alector. MeiraGTx is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MeiraGTx $81.39M 10.68 -$114.20M -$1.48 N/A Alector $21.05M 9.36 -$142.93M -$1.19 N/A

Is MGTX or ALEC more profitable?

MeiraGTx has a net margin of -151.12% compared to Alector's net margin of -680.83%. Alector's return on equity of -295.17% beat MeiraGTx's return on equity. Company Net Margins Return on Equity Return on Assets MeiraGTx -151.12% -1,065.47% -54.96% Alector -680.83% -295.17% -40.95%

Does the media prefer MGTX or ALEC?

In the previous week, Alector had 1 more articles in the media than MeiraGTx. MarketBeat recorded 6 mentions for Alector and 5 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 1.16 beat Alector's score of 0.93 indicating that MeiraGTx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MeiraGTx 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alector 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ABUS or ALEC more profitable?

Arbutus Biopharma has a net margin of 83.95% compared to Alector's net margin of -680.83%. Arbutus Biopharma's return on equity of 129.32% beat Alector's return on equity. Company Net Margins Return on Equity Return on Assets Arbutus Biopharma 83.95% 129.32% 112.24% Alector -680.83% -295.17% -40.95%

Alector (ALEC) Competitors

$1.78 -0.18 (-8.97%)

Closing price 06/3/2026 04:00 PM Eastern

Extended Trading

$1.78 +0.01 (+0.28%)

As of 07:33 AM Eastern

Compare

ALEC vs. CGEM, SPRY, MGTX, ABUS, and JANX

Should you buy Alector stock or one of its competitors? MarketBeat compares Alector with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Alector include Cullinan Therapeutics (CGEM), ARS Pharmaceuticals (SPRY), MeiraGTx (MGTX), Arbutus Biopharma (ABUS), and Janux Therapeutics (JANX). These companies are all part of the "pharmaceutical products" industry.

How does Alector compare to Cullinan Therapeutics?

Alector (NASDAQ:ALEC) and Cullinan Therapeutics (NASDAQ:CGEM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, media sentiment, institutional ownership, risk and dividends.

85.8% of Alector shares are held by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are held by institutional investors. 8.3% of Alector shares are held by insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Alector has higher revenue and earnings than Cullinan Therapeutics. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alector	$21.05M	9.36	-$142.93M	-$1.19	N/A
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A

Alector has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market. Comparatively, Cullinan Therapeutics has a beta of -0.01, suggesting that its share price is 101% less volatile than the broader market.

Cullinan Therapeutics has a net margin of 0.00% compared to Alector's net margin of -680.83%. Cullinan Therapeutics' return on equity of -51.45% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alector	-680.83%	-295.17%	-40.95%
Cullinan Therapeutics	N/A	-51.45%	-47.64%

In the previous week, Alector had 4 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 6 mentions for Alector and 2 mentions for Cullinan Therapeutics. Cullinan Therapeutics' average media sentiment score of 1.02 beat Alector's score of 0.93 indicating that Cullinan Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alector	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cullinan Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alector currently has a consensus target price of $3.63, indicating a potential upside of 104.23%. Cullinan Therapeutics has a consensus target price of $30.75, indicating a potential upside of 102.17%. Given Alector's higher probable upside, equities analysts plainly believe Alector is more favorable than Cullinan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Alector beats Cullinan Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Alector compare to ARS Pharmaceuticals?

ARS Pharmaceuticals (NASDAQ:SPRY) and Alector (NASDAQ:ALEC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, institutional ownership, valuation, earnings, risk, profitability and dividends.

ARS Pharmaceuticals currently has a consensus price target of $28.60, indicating a potential upside of 226.86%. Alector has a consensus price target of $3.63, indicating a potential upside of 104.23%. Given ARS Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe ARS Pharmaceuticals is more favorable than Alector.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

Alector has lower revenue, but higher earnings than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ARS Pharmaceuticals	$84.28M	10.31	-$171.30M	-$2.01	N/A
Alector	$21.05M	9.36	-$142.93M	-$1.19	N/A

In the previous week, Alector had 4 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 6 mentions for Alector and 2 mentions for ARS Pharmaceuticals. ARS Pharmaceuticals' average media sentiment score of 0.93 equaled Alector'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ARS Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alector	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ARS Pharmaceuticals has a net margin of -200.00% compared to Alector's net margin of -680.83%. ARS Pharmaceuticals' return on equity of -153.61% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ARS Pharmaceuticals	-200.00%	-153.61%	-60.85%
Alector	-680.83%	-295.17%	-40.95%

ARS Pharmaceuticals has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market. Comparatively, Alector has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market.

68.2% of ARS Pharmaceuticals shares are owned by institutional investors. Comparatively, 85.8% of Alector shares are owned by institutional investors. 33.8% of ARS Pharmaceuticals shares are owned by insiders. Comparatively, 8.3% of Alector shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

ARS Pharmaceuticals beats Alector on 9 of the 15 factors compared between the two stocks.

How does Alector compare to MeiraGTx?

MeiraGTx (NASDAQ:MGTX) and Alector (NASDAQ:ALEC) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, risk, analyst recommendations, earnings and institutional ownership.

67.5% of MeiraGTx shares are held by institutional investors. Comparatively, 85.8% of Alector shares are held by institutional investors. 7.5% of MeiraGTx shares are held by insiders. Comparatively, 8.3% of Alector shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Alector had 1 more articles in the media than MeiraGTx. MarketBeat recorded 6 mentions for Alector and 5 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 1.16 beat Alector's score of 0.93 indicating that MeiraGTx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MeiraGTx	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alector	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MeiraGTx has a net margin of -151.12% compared to Alector's net margin of -680.83%. Alector's return on equity of -295.17% beat MeiraGTx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MeiraGTx	-151.12%	-1,065.47%	-54.96%
Alector	-680.83%	-295.17%	-40.95%

MeiraGTx presently has a consensus price target of $25.83, suggesting a potential upside of 175.12%. Alector has a consensus price target of $3.63, suggesting a potential upside of 104.23%. Given MeiraGTx's stronger consensus rating and higher probable upside, analysts plainly believe MeiraGTx is more favorable than Alector.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

MeiraGTx has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market. Comparatively, Alector has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market.

MeiraGTx has higher revenue and earnings than Alector. MeiraGTx is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$81.39M	10.68	-$114.20M	-$1.48	N/A
Alector	$21.05M	9.36	-$142.93M	-$1.19	N/A

Summary

MeiraGTx beats Alector on 10 of the 17 factors compared between the two stocks.

How does Alector compare to Arbutus Biopharma?

Arbutus Biopharma (NASDAQ:ABUS) and Alector (NASDAQ:ALEC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

In the previous week, Alector had 5 more articles in the media than Arbutus Biopharma. MarketBeat recorded 6 mentions for Alector and 1 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 1.28 beat Alector's score of 0.93 indicating that Arbutus Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Arbutus Biopharma	Positive
Alector	Positive

Arbutus Biopharma has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market. Comparatively, Alector has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market.

Arbutus Biopharma has a net margin of 83.95% compared to Alector's net margin of -680.83%. Arbutus Biopharma's return on equity of 129.32% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma	83.95%	129.32%	112.24%
Alector	-680.83%	-295.17%	-40.95%

Arbutus Biopharma currently has a consensus price target of $5.00, indicating a potential upside of 14.94%. Alector has a consensus price target of $3.63, indicating a potential upside of 104.23%. Given Alector's stronger consensus rating and higher possible upside, analysts clearly believe Alector is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arbutus Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

Arbutus Biopharma has higher earnings, but lower revenue than Alector. Alector is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma	$14.08M	61.03	-$33.50M	$0.83	5.24
Alector	$21.05M	9.36	-$142.93M	-$1.19	N/A

43.8% of Arbutus Biopharma shares are held by institutional investors. Comparatively, 85.8% of Alector shares are held by institutional investors. 19.9% of Arbutus Biopharma shares are held by insiders. Comparatively, 8.3% of Alector shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Arbutus Biopharma beats Alector on 10 of the 16 factors compared between the two stocks.

How does Alector compare to Janux Therapeutics?

Alector (NASDAQ:ALEC) and Janux Therapeutics (NASDAQ:JANX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk.

Janux Therapeutics has lower revenue, but higher earnings than Alector. Janux Therapeutics is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alector	$21.05M	9.36	-$142.93M	-$1.19	N/A
Janux Therapeutics	$10M	82.87	-$113.62M	-$1.84	N/A

Alector has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market. Comparatively, Janux Therapeutics has a beta of 2.53, meaning that its stock price is 153% more volatile than the broader market.

85.8% of Alector shares are owned by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are owned by institutional investors. 8.3% of Alector shares are owned by company insiders. Comparatively, 7.9% of Janux Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Alector currently has a consensus target price of $3.63, indicating a potential upside of 104.23%. Janux Therapeutics has a consensus target price of $45.85, indicating a potential upside of 237.35%. Given Janux Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Janux Therapeutics is more favorable than Alector.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
Janux Therapeutics	2 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.60

In the previous week, Alector had 5 more articles in the media than Janux Therapeutics. MarketBeat recorded 6 mentions for Alector and 1 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 1.43 beat Alector's score of 0.93 indicating that Janux Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Alector	Positive
Janux Therapeutics	Positive

Janux Therapeutics has a net margin of 0.00% compared to Alector's net margin of -680.83%. Janux Therapeutics' return on equity of -12.93% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alector	-680.83%	-295.17%	-40.95%
Janux Therapeutics	N/A	-12.93%	-12.23%

Summary

Janux Therapeutics beats Alector on 11 of the 17 factors compared between the two stocks.

Get Alector News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALEC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALEC vs. The Competition

Export

Metric	Alector	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$216.50M	$3.24B	$6.47B	$12.54B
Dividend Yield	N/A	2.38%	2.69%	5.22%
P/E Ratio	-1.49	17.78	22.17	24.18
Price / Sales	9.36	315.63	524.01	112.26
Price / Cash	N/A	111.64	41.34	57.13
Price / Book	6.34	6.63	9.78	6.72
Net Income	-$142.93M	$24.20M	$3.57B	$337.19M
7 Day Performance	-17.44%	-4.39%	-2.50%	-0.75%
1 Month Performance	N/A	N/A	N/A	-1.69%
1 Year Performance	14.52%	45.50%	26.49%	33.09%

Alector Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALEC Alector	3.3894 of 5 stars	$1.78 -9.0%	$3.63 +104.2%	+19.9%	$216.50M	$21.05M	N/A	270	Insider Trade High Trading Volume
CGEM Cullinan Therapeutics	3.5102 of 5 stars	$16.44 +7.0%	$30.75 +87.0%	+69.8%	$944M	N/A	N/A	30	Positive News
SPRY ARS Pharmaceuticals	2.8486 of 5 stars	$9.07 -3.5%	$28.60 +215.3%	-39.8%	$933.45M	$84.28M	N/A	90	Analyst Upgrade
MGTX MeiraGTx	3.1934 of 5 stars	$10.66 +6.6%	$25.83 +142.5%	+69.5%	$926.10M	$79.76M	N/A	300	Positive News High Trading Volume
ABUS Arbutus Biopharma	2.2303 of 5 stars	$4.56 -0.9%	$5.00 +9.6%	+26.1%	$908.68M	$191.45M	5.49	90	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALEC) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alector (ALEC) Competitors

ALEC vs. CGEM, SPRY, MGTX, ABUS, and JANX

How does Alector compare to Cullinan Therapeutics?

Summary

How does Alector compare to ARS Pharmaceuticals?

Summary

How does Alector compare to MeiraGTx?

Summary

How does Alector compare to Arbutus Biopharma?

Summary

How does Alector compare to Janux Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALEC vs. The Competition

Alector Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alector (ALEC) Competitors

ALEC vs. CGEM, SPRY, MGTX, ABUS, and JANX

How does Alector compare to Cullinan Therapeutics?

Do institutionals & insiders believe in ALEC or CGEM?

Which has higher valuation and earnings, ALEC or CGEM?

Which has more risk and volatility, ALEC or CGEM?

Is ALEC or CGEM more profitable?

Does the media refer more to ALEC or CGEM?

Do analysts prefer ALEC or CGEM?

Summary

How does Alector compare to ARS Pharmaceuticals?

Do analysts recommend SPRY or ALEC?

Which has stronger valuation and earnings, SPRY or ALEC?

Does the media prefer SPRY or ALEC?

Is SPRY or ALEC more profitable?

Which has more volatility & risk, SPRY or ALEC?

Do institutionals and insiders believe in SPRY or ALEC?

Summary

How does Alector compare to MeiraGTx?

Do institutionals & insiders hold more shares of MGTX or ALEC?

Does the media prefer MGTX or ALEC?

Is MGTX or ALEC more profitable?

Do analysts recommend MGTX or ALEC?

Which has more volatility and risk, MGTX or ALEC?

Which has higher valuation and earnings, MGTX or ALEC?

Summary

How does Alector compare to Arbutus Biopharma?

Does the media prefer ABUS or ALEC?

Which has more risk and volatility, ABUS or ALEC?

Is ABUS or ALEC more profitable?

Do analysts rate ABUS or ALEC?

Which has better valuation and earnings, ABUS or ALEC?

Do insiders & institutionals believe in ABUS or ALEC?

Summary

How does Alector compare to Janux Therapeutics?

Which has higher earnings and valuation, ALEC or JANX?

Which has more volatility & risk, ALEC or JANX?

Do insiders and institutionals believe in ALEC or JANX?

Do analysts recommend ALEC or JANX?

Does the media refer more to ALEC or JANX?

Is ALEC or JANX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALEC vs. The Competition

Alector Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools